FSJ.L

James Fisher and Sons Plc
Fisher (James) - Completion of Disposal of Martek Holdings Limited
6th September 2024, 13:10
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2885D
Fisher (James) & Sons plc
06 September 2024
 

Fisher (James) & Sons plc

 

Completion of Disposal of Martek Holdings Limited for £12.1 million

 

James Fisher and Sons plc (FSJ.L) ("James Fisher" or the "Company" and, together with its subsidiaries, the "Group"), is pleased to announce that it has completed the sale of Martek Holdings Limited and its subsidiaries ("Martek" or the "Business") to a regional fund managed by Foresight Group ("Foresight") and the Management team ("the Foresight

Group ("Foresight") for a total cash consideration of £12.1 million ("Total Consideration").

 

The Total Consideration comprises an initial payment of £10.6 million and an unconditional deferred element, of £1.5 million, payable in two equal instalments of £0.75 million on the first and second anniversary of the transaction completion date.

 

Headquartered in the UK, Martek is a leading international distributor of premium mission and life-critical safety, monitoring and medical equipment to the maritime industry. The Business forms part of James Fisher's Maritime Transport Division and employs around 50 people. In the year ended 31 December 2023, Martek generated revenue of £11.6 million and profit before tax of £1.4 million

 

The Disposal is in line with James Fisher's strategy to simplify and focus its portfolio through the sale of non-core assets. The net proceeds will be used to reduce leverage and strengthen the Group's balance sheet. Together with the sale of RMSpumptools completed in July 2024, the Disposal will support a further reduction in leverage towards a target range of 1.0 to 1.5 times Net Debt to EBITDA.

 

Jean Vernet, Chief Executive Officer of James Fisher, said:

"The sale of Martek continues our strategy to simplify the business portfolio and ensure investment remains focused on our core customer markets, including innovative new product development.

 

"We are confident that the Business will continue its success under Foresight's ownership, and on behalf of everyone at James Fisher, I would like to thank the Martek team for their contribution."

 

Enquiries


James Fisher and Sons plc

 

Jean Vernet, Karen Hayzen-Smith

+44 20 7614 9503



FTI Consulting

(PR Adviser)

Richard Mountain, Susanne Yule

+44 20 3727 1340

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISSSAFDMELSESU]]>
TwitterFacebookLinkedIn